All In Biotech

Drug Trial Radar · NCT04647773

To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo- and Pregabalin Capsule-Controlled, 13-Week, Adaptive-design Phase 2/3 Study to Evaluate the Efficacy and Safety of HSK16149 Capsules in Chinese Patients With Diabetic Peripheral Neuropathic Pain

Last checked: Nov 20, 2026Latest source record: Dec 1, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 687 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

687

Planned (sponsor's estimate)

Start

Dec 2, 2020

Primary completion

Nov 9, 2022

Study completion Nov 16, 2022

Sponsor

Sponsor type
Industry
First posted
Dec 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Investigate the efficacy and safety of HSK16149 capsules in Chinese diabetic peripheral neuropathic pain (DPNP) following 13 weeks treatment in comparison to placebo.

Conditions

  • Diabetic Peripheral Neuropathic Pain

Interventions

  • HSK16149 20mg BIDDrug

    HSK16149 20mg, orally twice a day, treatment period; 13-weeks fixed dose.

  • HSK16149 40mg BIDDrug

    HSK16149 40mg, orally twice a day, treatment period; 13-weeks fixed dose.

  • HSK16149 60mg BIDDrug

    HSK16149 60mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.

  • HSK16149 80mg BIDDrug

    HSK16149 80mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.

  • Pregabalin 150mg BIDDrug

    Pregabalin 150mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.

  • Placebo BIDDrug

    Placebo, orally twice a day, treatment period; 13-weeks fixed dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare the change from baseline in Average Daily Pain Score(ADPS) between HSK16149 and placebo at week 5.Time frame: Baseline and week 5
  2. Compare the change from baseline in Average Daily Pain Score (ADPS) between HSK16149 and placebo at week 13.Time frame: Baseline and week 13

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.